BioCryst Pharmaceuticals BCRX Other revenues — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's other revenues — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's other revenues — total revenues?
- BioCryst Pharmaceuticals (BCRX) reported other revenues — total revenues of $5.05M in Q1 2026.
- How has BioCryst Pharmaceuticals's other revenues — total revenues changed year-over-year?
- BioCryst Pharmaceuticals's other revenues — total revenues decreased by 55.3% year-over-year, from $11.29M to $5.05M.
- What is the long-term trend for BioCryst Pharmaceuticals's other revenues — total revenues?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's other revenues — total revenues has grown at a -4.3% compound annual growth rate (CAGR), from $34.62M to $29.02M.
- What does other revenues — total revenues mean?
- This metric represents the portion of total corporate revenue derived from ancillary business activities, contract services, or secondary product lines outside of the company's primary therapeutic franchises. It captures income streams generated from partnerships, licensing arrangements, or specialized service contracts that supplement core drug development revenue. Monitoring this segment helps investors assess the diversification of the company's income base and the success of its broader commercialization strategy beyond its main product portfolio.